Yes, Paxlovid rebound is contagious. Studies have confirmed that people shed live, infectious virus during the rebound period, and there are documented cases of likely transmission to close contacts. If your symptoms and positive test have returned after finishing Paxlovid, you should treat yourself as contagious and take the same precautions you would during any active COVID infection.
What the Evidence Shows About Contagiousness
Two separate studies have confirmed the presence of culturable, infectious virus during Paxlovid rebound, meaning the virus detected on tests isn’t just leftover genetic fragments. It’s live and capable of infecting other people. A report published in the New England Journal of Medicine documented two patients who likely transmitted COVID to close contacts specifically during their rebound period. The researchers concluded that higher viral loads during rebound, combined with the ease of growing the virus in lab cultures, strongly suggest patients are contagious during this phase.
One observational study found that people experiencing rebound shed infectious virus for roughly 14 days, compared to just 3 days in people whose infections resolved without a rebound. That’s a significantly longer window of contagiousness, and it catches many people off guard because they assumed they were already past the infectious stage.
Why Rebound Happens
Paxlovid works by blocking the virus’s ability to replicate. When you take it early in your infection, it drives viral levels down quickly, which is why most people feel better fast. But the drug also has an unintended side effect on your body’s immune learning process.
Normally, as the virus infects cells in your airways, your immune system ramps up its response. Paxlovid is so effective at slowing viral replication that it preserves many of the cells the virus would have otherwise infected and destroyed. This is good in the short term because it limits damage. But it also means your immune system may not get the full signal it needs to mount a strong adaptive response. Think of it as the fire department arriving before the smoke alarms have fully gone off.
After the standard 5-day course ends and the drug clears your system, any virus that wasn’t completely eliminated can start replicating again. Those preserved, still-vulnerable cells provide fresh fuel. If your immune system hasn’t caught up by that point, the virus bounces back. This is the rebound: not a new infection or a resistant strain, but the original virus finding room to grow again. Genomic sequencing has confirmed that rebound virus shows no resistance mutations, which means Paxlovid still works against it.
How Rebound Typically Plays Out
Rebound usually begins 2 to 8 days after completing the 5-day course of Paxlovid. You may have tested negative and felt fine for a day or two before symptoms return. The returning symptoms are generally similar to the initial infection, though many people report them as milder. A rapid antigen test will typically turn positive again during rebound, reflecting the renewed viral activity.
If you test positive again after having tested negative post-treatment, that’s a strong signal you’re in a rebound phase and should consider yourself infectious. Given the evidence that viral shedding can last up to 14 days during rebound, it’s worth continuing to test before resuming close contact with others, especially anyone who is older or immunocompromised.
What to Do During Rebound
The practical steps are straightforward. Isolate or mask around others just as you would with any active COVID infection. Use rapid antigen tests to track whether you’re still shedding virus. A negative test on two consecutive days, spaced at least 48 hours apart, is a reasonable signal that you’re no longer contagious, though no approach is foolproof.
There is no established protocol for retreating rebound with a second course of Paxlovid. Most people clear the virus on their own once their immune system catches up, which is what viral modeling studies predict. The rebound itself, while frustrating, doesn’t indicate that the initial treatment failed or that you’re at higher risk for severe illness.
Can Rebound Be Prevented?
A phase 2 clinical trial called EPIC-IC tested whether extending Paxlovid beyond the standard 5 days could reduce rebound, specifically in immunocompromised patients. The results were striking: 17.3% of patients on the standard 5-day course experienced viral rebound, compared to just 2.1% on a 10-day course and 2% on a 15-day course. The trial enrolled 156 patients across 73 sites in nine countries.
These findings are promising but currently apply mainly to immunocompromised individuals, and longer courses aren’t yet part of standard prescribing guidelines for the general population. For most people, the 5-day course remains the default. If you’re immunocompromised and concerned about rebound, it’s worth discussing extended treatment with whoever prescribed your Paxlovid.